Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical use

Movement Disorders

Volumn 11, Issue 1, 1996, Pages 24-26

  Pappert, Eric J ^a   Buhrfiend, Colleen ^a   Lipton, Jack W ^a   Carvey, Paul M ^a   Stebbins, Glenn T ^a   Goetz, Christopher G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ascorbate; Levodopa; Light; Liquid; Parkinson's disease; Temperature

Indexed keywords

ASCORBIC ACID; CARBIDOPA PLUS LEVODOPA;

ARTICLE; DARKNESS; DRUG STABILITY; FREEZING; LIGHT EXPOSURE; PARKINSON DISEASE; PRIORITY JOURNAL; TEMPERATURE; TIME;

ANTIPARKINSON AGENTS; ASCORBIC ACID; CARBIDOPA; DRUG COMBINATIONS; DRUG STABILITY; DRUG STORAGE; HUMANS; LEVODOPA; LIGHT; PARKINSON DISEASE; TEMPERATURE; TIME FACTORS;

EID: 0030071016     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110106     Document Type: Article

References (10)

1. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology 1974;24:431-441.
2. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-371.
3. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378.
4. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson J. "On-off" phenomenon in Parkinson's disease: relationship to L-DOPA absorption and transport. N Engl J Med 1984;310:483-488.
5. Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with severe fluctuations. Neurology 1988; 38:1143-1146.
6. Cedarbaum JM, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990;40: 995-997.
7. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: A pilot study. Neurology 1993;43:1036-1039.
8. Singh A, Tanner CM, Wasserstein P, Kurth M, Tetrud J. Orally administered levodopa-carbidopa (LD-CD) solution reduces "off-time" in Parkinson's disease (PD) [Abstract]. Neurology 1993;43:A197.
9. Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994;9:463-465.
10. Wagner J, Vitali P, Palfreyman MG, Zraika M, Huot S. Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high-performance liquid chromatography with electrochemical detection. J Neurochem 1982;38:1241-1254.